Abstract
sICAM-1 and beta-2 microglobulin (beta-2M) serum levels were measured in 143 breast cancer patients and 43 controls. The patients were divided into three groups. A: new patients; B: patients on long term follow-up and C: metastatic patients. In all patients the mean +/-1SD sICAM-1 and beta-2M serum levels were significantly higher than normal controls (p <0.001 and p <0.0001, respectively). Analysis of the three groups showed that for both sICAM-1 and beta-2M, Groups A and C had similar serum levels, which differed significantly from Group B. sICAM-1 of Group B was similar to controls, while beta-2M of Group B was significantly higher than controls. During the study 20 patients relapsed. Initial high levels of sICAM-1 were observed in 20% and beta-2M in 50% of patients. These data suggest that sICAM-1 and beta-2M level indicate host cell-mediated immunity against tumor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
